Joseph-McCarthy Diane, Campbell Arthur J, Kern Gunther, Moustakas Demetri
Infection Innovative Medicines Unit, AstraZeneca, R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
J Chem Inf Model. 2014 Mar 24;54(3):693-704. doi: 10.1021/ci400731w. Epub 2014 Feb 19.
Fragment-based lead discovery and design has and continues to show increasing promise in drug discovery. In this article, the current state of the art in terms of hot-spot characterization, fragment screening techniques, and fragment-based design is discussed. Three overall fragment-based lead generation strategies are explored and involve the chemical biology characterization of biological targets via fragment screening, fragment screening as a complementary approach to high-throughput screening of drug-like compounds, and direct fragment-based drug discovery, respectively. The evolution and development of fragment libraries is described. With an emphasis on computational approaches and the strategies applied at AstraZeneca, the review illustrates how integration of data from one regime can inform the design of experiments in the other, ultimately leading to the discovery of high quality chemical matter.
基于片段的先导化合物发现与设计在药物研发中已经并将继续展现出越来越大的前景。本文讨论了在热点表征、片段筛选技术和基于片段的设计方面的当前技术水平。探索了三种总体的基于片段的先导化合物生成策略,分别涉及通过片段筛选对生物靶点进行化学生物学表征、片段筛选作为类药物化合物高通量筛选的补充方法以及直接基于片段的药物发现。描述了片段库的演变与发展。本文着重介绍计算方法以及阿斯利康应用的策略,阐述了如何将来自一个领域的数据整合用于指导另一个领域的实验设计,最终实现高质量化学物质的发现。